PIOGLITAZONE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Pioglitazone Hydrochloride patents expire, and when can generic versions of Pioglitazone Hydrochloride launch?
Pioglitazone Hydrochloride is a drug marketed by Accord Hlthcare, Annora Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Macleods Pharms Ltd, Mylan Pharms Inc, Nostrum Labs Inc, Prinston Inc, Puracap Pharm Llc, Sandoz, Shuangcheng, Teva Pharms Usa, Torrent Pharms Ltd, Zydus Pharms Usa Inc, and Mylan. and is included in twenty-two NDAs.
The generic ingredient in PIOGLITAZONE HYDROCHLORIDE is metformin hydrochloride; pioglitazone hydrochloride. There are forty-nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.
Summary for PIOGLITAZONE HYDROCHLORIDE
Recent Clinical Trials for PIOGLITAZONE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Minnesota | Phase 2 |
Wuhan Union Hospital, China | Phase 2 |
University of Campinas, Brazil | Phase 4 |